Inhibitory Effect of OP-41483.ALPHA.-CD, a Prostacyclin Analog, on Peripheral Vascular Lesion Models in Rats.
スポンサーリンク
概要
- 論文の詳細を見る
The effect of a chemically stable prostacyclin analog, OP-41483 α-cyclodextrin clathrate (OP-41483·α-CD), on vascular lesions, platelet aggregation and blood pressure were examined and compared with those of prostaglandin E<SUB>1</SUB> α-cyclodextrin clathrate (PGE<SUB>1</SUB>·CD) in in vivo rat models. 1) In the laurate (1 mg/leg, i.a.)-induced arterial thrombotic model, OP-41483·α-CD (1 μg/kg/min, i.v.) prevented the progression of femoral arterial vascular lesions and enhanced the development of collaterals in the femoral artery. PGE<SUB>1</SUB>·CD did not inhibit the progression of vascular damages. 2) In the model of vasoconstriction induced by epinephrine (0.05 mg/tail, s.c.) and ergotamine (2 mg/kg, s.c.), OP-41483·α-CD and PGE<SUB>1</SUB>·CD, at 1 μg/kg/min, inhibited the progress of tail gangrene and lessened the decrease in tail cutaneous blood flow. 3) OP-41483·α-CD (1 μg/kg/min) suppressed the ADP (0.1 mg/kg/min, i.v.)-induced decrease in the number of circulating platelets without affecting the change in blood pressure. In contrast, PGE<SUB>1</SUB>·CD (3 μg/kg/min) inhibited ADP-induced thrombocytopenia with a decrease in blood pressure. These results indicate that OP-41483·α-CD has antiplatelet and cutaneous blood flow improving activities that are greater than its hypotensive effect and may be of therapeutic potential in peripheral vascular diseases.
- 公益社団法人 日本薬理学会の論文
著者
-
Fujitani Buichi
Exploratory Research Laboratories, Dainippon Pharmaceutical Co., Ltd.
-
Wakitani Korekiyo
Minase Research Institute, Ono Pharmaceutical Co., Ltd.
-
Takakuwa Toshio
Minase Research Institute, Ono Pharmaceutical Co., Ltd.
-
Sugioka Makiko
Minase Research Institute, Ono Pharmaceutical Co., Ltd.
-
Aishita Hideki
Minase Research Institute, Ono Pharmaceutical Co., Ltd.
関連論文
- Inhibitory Effect of OP-41483.ALPHA.-CD, a Prostacyclin Analog, on Peripheral Vascular Lesion Models in Rats.
- Involvement of Arachidonate Metabolites on the Stroke Onset in Stroke-Prone Spontaneously Hypertensive Rats (SHRSP)
- In Vivo Pharmacologic Profile of ONO-1078: A Potent, Selective and Orally Active Peptide Leukotriene (LT) Antagonist.
- In Vitro Antagonism of ONO-1078, a Newly Developed Anti-Asthma Agent, against Peptide Leukotrienes in Isolated Guinea Pig Tissues.